This Therapeutic Nuclear Drug market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $1.94 billion in 2024 to $2.23 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing regulatory approvals, increasing use of patient-specific information, improving dosimetry techniques, increasing awareness of nuclear medicines and increasing investment in research and development activities.
The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $3.86 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to the shift towards personalized medicine, the rising demand for healthcare infrastructure improvements, the growing geriatric population, the growing number of diagnostic imaging procedures, and the rise of personalized care delivery. Major trends in the forecast period include nanoparticle-based delivery systems, advancements in radionuclide therapy, hybrid imaging systems, radiopharmaceutical manufacturing and development of alpha-emitting radiopharmaceuticals, and integration of machine learning and artificial intelligence.
The rising prevalence of cancer is expected to drive the growth of the therapeutic nuclear drug market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predisposition. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted, effective therapies that help reduce tumor size, alleviate symptoms, and improve patients' quality of life. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based UN agency, projected that over 35 million new cancer cases will be diagnosed by 2050, marking a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of cancer is fueling the expansion of the therapeutic nuclear drug market.
Major companies in the therapeutic nuclear drug market are increasingly forming strategic partnerships to strengthen their competitive position. These collaborations are crucial for enhancing research and development capabilities, speeding up the commercialization of new therapies, and improving access to innovative treatments by leveraging shared resources and expertise. For example, in July 2022, DeepC, a Germany-based software company, partnered with PAIRE, a U.S.-based AI solutions provider, to advance nuclear medicine diagnostics. Through this partnership, they aim to improve the precision and efficiency of nuclear medicine diagnostics by integrating PAIRE’s AI solution, Pionus, into DeepC’s deepcOS platform, which enhances the interpretation of PET/CT scans.
In May 2024, Telix Pharmaceuticals Limited, an Australian biotechnology company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix’s therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences, a US-based biotech firm, specializes in developing next-generation nuclear therapeutic medicines.
Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals.
North America was the largest region in the therapeutic nuclear drug market in 2023. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Therapeutic nuclear drugs are medications that use radioactive materials to target and treat diseases, primarily cancer. These drugs employ targeted radiopharmaceuticals that bind to cancer cells and deliver a therapeutic dose of radiation directly to them, aiming to destroy the cancerous cells while minimizing damage to surrounding healthy tissue.
The main types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223, for example, is used mainly to treat prostate cancer that has metastasized to the bones. These drugs are distributed through various channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are utilized in applications like treating thyroid cancer, bone metastases, lymphoma, and other conditions.
The therapeutic nuclear drugs market research report is one of a series of new reports that provides therapeutic nuclear drugs market statistics, including the therapeutic nuclear drugs industry global market size, regional shares, competitors with a therapeutic nuclear drugs market share, detailed therapeutic nuclear drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the therapeutic nuclear drugs industry. This therapeutic nuclear drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The therapeutic nuclear drug market size has grown rapidly in recent years. It will grow from $1.94 billion in 2024 to $2.23 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing regulatory approvals, increasing use of patient-specific information, improving dosimetry techniques, increasing awareness of nuclear medicines and increasing investment in research and development activities.
The therapeutic nuclear drug market size is expected to see rapid growth in the next few years. It will grow to $3.86 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to the shift towards personalized medicine, the rising demand for healthcare infrastructure improvements, the growing geriatric population, the growing number of diagnostic imaging procedures, and the rise of personalized care delivery. Major trends in the forecast period include nanoparticle-based delivery systems, advancements in radionuclide therapy, hybrid imaging systems, radiopharmaceutical manufacturing and development of alpha-emitting radiopharmaceuticals, and integration of machine learning and artificial intelligence.
The rising prevalence of cancer is expected to drive the growth of the therapeutic nuclear drug market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is becoming more prevalent due to factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predisposition. Therapeutic nuclear drugs play a crucial role in cancer treatment by offering targeted, effective therapies that help reduce tumor size, alleviate symptoms, and improve patients' quality of life. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based UN agency, projected that over 35 million new cancer cases will be diagnosed by 2050, marking a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of cancer is fueling the expansion of the therapeutic nuclear drug market.
Major companies in the therapeutic nuclear drug market are increasingly forming strategic partnerships to strengthen their competitive position. These collaborations are crucial for enhancing research and development capabilities, speeding up the commercialization of new therapies, and improving access to innovative treatments by leveraging shared resources and expertise. For example, in July 2022, DeepC, a Germany-based software company, partnered with PAIRE, a U.S.-based AI solutions provider, to advance nuclear medicine diagnostics. Through this partnership, they aim to improve the precision and efficiency of nuclear medicine diagnostics by integrating PAIRE’s AI solution, Pionus, into DeepC’s deepcOS platform, which enhances the interpretation of PET/CT scans.
In May 2024, Telix Pharmaceuticals Limited, an Australian biotechnology company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix’s therapeutic pipeline with the investigational drug Samarium-153-DOTMP, which targets bone metastases and osteosarcoma. QSAM Biosciences, a US-based biotech firm, specializes in developing next-generation nuclear therapeutic medicines.
Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals.
North America was the largest region in the therapeutic nuclear drug market in 2023. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic nuclear drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Therapeutic nuclear drugs are medications that use radioactive materials to target and treat diseases, primarily cancer. These drugs employ targeted radiopharmaceuticals that bind to cancer cells and deliver a therapeutic dose of radiation directly to them, aiming to destroy the cancerous cells while minimizing damage to surrounding healthy tissue.
The main types of therapeutic nuclear drugs include radium-223, lutetium-177, iodine-131, and others. Radium-223, for example, is used mainly to treat prostate cancer that has metastasized to the bones. These drugs are distributed through various channels such as hospitals, ambulatory surgical centers, and cancer research institutes, and are utilized in applications like treating thyroid cancer, bone metastases, lymphoma, and other conditions.
The therapeutic nuclear drugs market research report is one of a series of new reports that provides therapeutic nuclear drugs market statistics, including the therapeutic nuclear drugs industry global market size, regional shares, competitors with a therapeutic nuclear drugs market share, detailed therapeutic nuclear drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the therapeutic nuclear drugs industry. This therapeutic nuclear drug research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The therapeutic nuclear drug market consists of sales of yttrium-90, actinium-225, bismuth-213, therapeutic iodine-123, and copper-67. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Therapeutic Nuclear Drug Market Characteristics3. Therapeutic Nuclear Drug Market Trends and Strategies4. Therapeutic Nuclear Drug Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Therapeutic Nuclear Drug Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Therapeutic Nuclear Drug Market34. Recent Developments in the Therapeutic Nuclear Drug Market
5. Global Therapeutic Nuclear Drug Growth Analysis and Strategic Analysis Framework
6. Therapeutic Nuclear Drug Market Segmentation
7. Therapeutic Nuclear Drug Market Regional and Country Analysis
8. Asia-Pacific Therapeutic Nuclear Drug Market
9. China Therapeutic Nuclear Drug Market
10. India Therapeutic Nuclear Drug Market
11. Japan Therapeutic Nuclear Drug Market
12. Australia Therapeutic Nuclear Drug Market
13. Indonesia Therapeutic Nuclear Drug Market
14. South Korea Therapeutic Nuclear Drug Market
15. Western Europe Therapeutic Nuclear Drug Market
16. UK Therapeutic Nuclear Drug Market
17. Germany Therapeutic Nuclear Drug Market
18. France Therapeutic Nuclear Drug Market
19. Italy Therapeutic Nuclear Drug Market
20. Spain Therapeutic Nuclear Drug Market
21. Eastern Europe Therapeutic Nuclear Drug Market
22. Russia Therapeutic Nuclear Drug Market
23. North America Therapeutic Nuclear Drug Market
24. USA Therapeutic Nuclear Drug Market
25. Canada Therapeutic Nuclear Drug Market
26. South America Therapeutic Nuclear Drug Market
27. Brazil Therapeutic Nuclear Drug Market
28. Middle East Therapeutic Nuclear Drug Market
29. Africa Therapeutic Nuclear Drug Market
30. Therapeutic Nuclear Drug Market Competitive Landscape and Company Profiles
31. Therapeutic Nuclear Drug Market Other Major and Innovative Companies
35. Therapeutic Nuclear Drug Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Therapeutic Nuclear Drug Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on therapeutic nuclear drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for therapeutic nuclear drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The therapeutic nuclear drug market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Radium-223; Lutetium-177; Iodine-131; Other Types2) By Distribution Channel: Hospitals; Ambulatory Surgical Centers (ASCs); Cancer Research Institutes
3) By Application: Thyroid; Bone Metastasis; Lymphoma; Other Applications
Subsegments:
1) Radium-223: Indications for prostate cancer; Mechanism of action; Dosage forms2) Lutetium-177: Applications in neuroendocrine tumors; Treatment protocols; Combination therapies
3) Iodine-131: Use in thyroid cancer; Dosage and administration; Safety and efficacy
4) Other Types: Additional therapeutic isotopes; Emerging treatments; Research and development trends
Key Companies Mentioned: Bayer AG; Novartis International AG; Siemens Healthineers AG; Ipsen S.a.; Jubilant DraxImage Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Therapeutic Nuclear Drug market report include:- Bayer AG
- Novartis International AG
- Siemens Healthineers AG
- Ipsen S.A.
- Jubilant DraxImage Inc.
- Mallinckrodt Pharmaceuticals PLC
- The Bracco Group
- Lantheus Medical Imaging Inc.
- Piramal Group
- Curium Pharmaceuticals
- Yantai Dongcheng Pharmaceutical Group Co. Ltd.
- Eckert & Ziegler
- Telix Pharmaceuticals Limited
- International Isotopes inc.
- Orano SA
- Q BioMed Inc.
- Molecular Targeting Technologies Inc
- Medi-Radiopharma Co. Ltd.
- Actinium Pharmaceuticals
- Fusion Pharmaceuticals
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 2.23 Billion |
Forecasted Market Value ( USD | $ 3.86 Billion |
Compound Annual Growth Rate | 14.7% |
Regions Covered | Global |
No. of Companies Mentioned | 21 |